A trial of desmopressin to reduce blood loss in patients undergoing spinal fusion for idiopathic scoliosis.
Desmopressin (DDAVP) has been reported to reduce bleeding in patients undergoing spinal fusion. To evaluate its efficacy in normal patients, 30 healthy young patients (ASA physical status I or II) undergoing spinal fusion for idiopathic scoliosis were randomly allocated to receive either 100 mL of physiologic saline solution (placebo group) or DDAVP (10 micrograms/m2 of body surface area) (DDAVP group) in a prospective, double-blind trial. Intraoperative blood loss was measured by weighing sponges and suction drainage and postoperative bleeding by wound drainage. The amount of blood loss expressed as a percent of the estimated blood volume was similar in both groups during the intraoperative period (67.0% +/- 28.8% [mean +/- SD] placebo group vs 57.4% +/- 26.5% DDAVP group), the postoperative period up to 24 h (32.5% +/- 6.4% placebo group vs 31.1% +/- 10.6% DDAVP group), and both periods (94.3% +/- 29.4% placebo group vs 88.2% +/- 30.7% DDAVP group). With the dose used in our study, we conclude that DDAVP does not reduce surgical bleeding in patients undergoing spinal fusion for idiopathic scoliosis.
Guay
J
J
Department of Anesthesiology, Sainte-Justine Hospital, Montreal, Quebec, Canada.
Reinberg
C
C
Poitras
B
B
David
M
M
Mathews
S
S
Lortie
L
L
Rivard
G E
GE
D000293:Adolescent; D016063:Blood Loss, Surgical / Q000517:prevention & control*; D003894:Deamino Arginine Vasopressin / Q000627:therapeutic use*; D005169:Factor VIII / Q000187:drug effects / Q000378:metabolism; D005260:Female; D006801:Humans; D008297:Male; D012600:Scoliosis / Q000209:etiology / Q000601:surgery*; D013123:Spinal Fusion / Q000009:adverse effects*; D014841:von Willebrand Factor / Q000187:drug effects / Q000378:metabolism
D014841:von Willebrand Factor; D005169:Factor VIII; D003894:Deamino Arginine Vasopressin